Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs

Genprex, Inc., a biopharmaceutical company focusing on developing gene therapies for oncology and diabetes, recently filed an 8-K form with the Securities and Exchange Commission providing crucial updates on its clinical trials and gene therapy programs.

The company’s Acclaim-1 clinical trial, a Phase 1/2 study, utilizes a combination of REQORSA and AstraZeneca’s Tagrisso® for late-stage Non-Small Cell Lung Cancer (NSCLC) patients with specific genetic mutations. Currently underway, this trial consists of a Phase 2a expansion portion that aims to enroll about 33 patients. An interim analysis is scheduled after treating 19 patients, with completion expected for the first half of 2025, followed by interim analyses in the latter half of the year. The Acclaim-1 trial holds Fast Track Designation from the U.S. FDA for the treatment combination in NSCLC patients.

In tandem, the Acclaim-3 clinical trial, also a Phase 1/2 study, focuses on a combination of REQORSA and Genentech, Inc.’s Tecentriq® for patients with extensive Small Cell Lung Cancer (SCLC). With an FDA Fast Track Designation and an Orphan Drug Designation under its belt, this trial is advancing with an anticipated enrollment of around 50 patients, with interim analysis planned for the second half of 2025.

Furthermore, Genprex discussed progress in its diabetes gene therapy program, which includes exclusive licensing of multiple technologies from the University of Pittsburgh for gene therapy solutions targeting Type 1 and Type 2 diabetes. The Company is currently evaluating and optimizing its diabetes product candidates in preclinical studies, with plans to move into research involving animal models in the second half of 2025. Research also extends to a non-viral lipid nanoparticle delivery system.

It is important to note that forward-looking statements within this report are subject to inherent risks, uncertainties, and assumptions. The company advises detailed scrutiny of associated risk factors, as mentioned in Genprex’s periodic reports filed with the SEC. Genprex disclaims any obligation to publicly update or revise forward-looking statements following the initial release, except as required by law.

Investors and stakeholders keen on the latest developments within Genprex’s transformative oncology and diabetes gene therapies can access additional details and the investor presentation slides on the company’s website, www.genprex.com.

As per this 8-K filing, Genprex did not disclose any financial statements but rather proffered essential information solely concerning the progress and potential future avenues of its pioneering programs in the field of gene therapy.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Genprex’s 8K filing here.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.